The Patent Finder
US

Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases

US 7,528,143 In force, term unresolved
OverviewFamilyAssignmentsSources & methods

Term ends no later than Nov 16, 2031 · Medium confidence

In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.

Filed Oct 26, 2006 as application 11/588,638 · Granted May 5, 2009
Base term plus 51 days of patent term adjustment (USPTO delay)
Today
20 years from filing
2006 2031
Clock starts
Oct 26, 2006
Ends no later than
Nov 16, 2031
Granted
May 5, 2009
base term patent term adjustment fee events Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
51
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term runs 51 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Oct 26, 2006, when this application, 11/588,638, was filedOct 26, 2026High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustment+51 days, USPTO patent term adjustment recordDec 16, 2026High confidence
Terminal disclaimer capDisclaimer on file (approved), reference document not resolvedno cap applied, and none guessedMedium confidence
Patent term extension+1796 days, USPTO 35 U.S.C. 156 certificateadded to Dec 16, 2026: Nov 16, 2031High confidence
Fee events3 of 3 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderno later than Nov 16, 2031Medium confidence

This family

US 7,528,143this patent
no later than Nov 2031
no later than Nov 2031
US 7,825,246In force
no later than Mar 2027
no later than Mar 2027
US 8,133,900In force
Sep 2027
Sep 2027
US 8,138,199In force
Jun 2028
Jun 2028
US 8,604,042Term ended
Oct 2026
Oct 2026
Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jan 19, 2007
Reel 18782, frame 251
Noronha, Glenn; Mak, Chi Ching; Cao, Jianguo; Renick, Joel; McPherson, Andrew; Zeng, Binqi; Pathak, Ved P.; Lohse, Daniel L.; Hood, John D.; Soll, Randall M.Targegen, Inc.Assignment of Assignor's Interest
Jan 23, 2007
Reel 18791, frame 911
Noronha, Glenn; Mak, Chi Ching; Cao, Jianguo; Renick, Joel; McPherson, Andrew; Zeng, Binqi; Pathak, Ved P.; Lohse, Daniel L.; Hood, John D.; Soll, Richard M.Targegen, Inc.Assignment of Assignor's Interest
Jul 31, 2013
Reel 30936, frame 578
Noronha, Glenn; Mak, Chi Ching; Cao, Jianguo; Renick, Joel; McPherson, Andrew; Zeng, Binqi; Pathak, Ved P.; Lohse, Daniel L.; Hood, John D.; Soll, Richard M.Targegen, Inc.Corrective Assignment to Correct the State of Incorporation from a California Corporation to a Delaware Corporation for the Assignee Previously Recorded on Reel 018791 Frame 0911. Assignor(S) Hereby Confirms the State of Incorporation for Targegen, Inc. to Be a Delaware Corporation..
Sep 19, 2013
Reel 31246, frame 401
Noronha, Glenn; Mak, Chi Ching; Cao, Jianguo; Renick, Joel; McPherson, Andrew; Zeng, Binqi; Pathak, Ved P.; Lohse, Daniel L.; Hood, John D.; Soll, Richard M.Targegen, Inc.Corrective Assignment to Correct the State of Incorporation from a California Corporation to a Delaware Corporation for the Assignee Previously Recorded on Reel 018782 Frame 0251. Assignor(S) Hereby Confirms the State of Incorporation for Targegen, Inc. to Be a Delaware Corporation.
May 25, 2017
Reel 42586, frame 643
Impact Therapeutics, Inc.Impact Biomedicines, Inc.Change of Name
May 25, 2017
Reel 42512, frame 179
Targegen, Inc.Impact Therapeutics, Inc.Assignment of Assignor's Interest
Nov 30, 2017
Reel 44572, frame 660
Impact Biomedicines, Inc.Lind S.A., LLC, as Collateral AgentSecurity Interest
Feb 12, 2018
Reel 44904, frame 628
Lind S.A. LLC, as Collateral AgentImpact Biomedicines, Inc.Release of Security Interest
Aug 21, 2019
Reel 50297, frame 562
Targegen, Inc.Impact Biomedicines, Inc.Corrective Assignment to Correct the Assignee's Name Previously Recorded at Reel: 042512 Frame: 0179. Assignor(S) Hereby Confirms the Assignment .

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited